Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Julia Saperia, research assistant (j.c.saperia@qmul.ac.uk),
  2. Deborah Ashby, professor of medical statistics,
  3. David Gunnell, professor of epidemiology
  1. Wolfson Institute of Preventive Medicine, Queen Mary, University of London, London EC1M 6BQ
  2. Department of Social Medicine, University of Bristol, Bristol BS8 2PR

    EDITOR—Our meta-analysis on the risk of suicide from selective serotonin reuptake inhibitors (SSRIs) was published last year.1 In the light of recently released data for paroxetine by its manufacturer, GlaxoSmithKline,2 we have updated our results.

    In our original analysis we were unable to distinguish between occurrences of non-fatal self harm and suicidal thoughts for patients in paroxetine trials. Our main analysis of these events therefore excluded the paroxetine data; in a sensitivity analysis we divided the events equally between self harm and …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular